+As economic woes of the COVID-19 pandemic deepen, strategies are being formulated to avoid the need for prolonged stay-at-home orders, while implementing risk-based quarantine, testing, contact tracing and surveillance protocols. Given limited resources and the significant economic, public health, and operational challenges of the current 14-day quarantine recommendation, it is vital to understand if shorter but equally effective quarantine and testing strategies can be deployed. To quantify the probability of post-quarantine transmission upon isolation of a positive test, we developed a mathematical model in which we varied quarantine duration and the timing of molecular tests for three scenarios of entry into quarantine. Specifically, we consider travel quarantine, quarantine of traced contacts with an unknown time if infection, and quarantine of cases with a known time of exposure. With a one-day delay between test and result, we found that testing on exit (or entry and exit) can reduce the duration of a 14-day quarantine by 50%, while testing on entry shortened quarantine by at most one day. Testing on exit more effectively reduces post-quarantine transmission than testing upon entry. Furthermore, we identified the optimal testing date within quarantines of varying duration, finding that testing on exit was most effective for quarantines lasting up to seven days. As a real-world validation of these principles, we analyzed the results of 4,040 SARS CoV-2 RT-PCR tests administered to offshore oil rig employees. Among the 47 positives obtained with a testing on entry and exit strategy, 16 cases that previously tested negative at entry were identified, with no further cases detected among employees following quarantine exit. Moreover, this strategy successfully prevented an expected nine offshore transmission events stemming from cases who had tested negative on the entry test, each one a serious concern for initiating rapid spread and a disabling outbreak in the close quarters of an offshore rig. This successful outcome highlights that appropriately timed testing can make shorter quarantines more effective, thereby minimizing economic impacts, disruptions to operational integrity, and COVID-related public health risks. +
++Since the Coronavirus Disease 2019 (COVID-19) pandemic, Brazil has the third-highest number of confirmed cases and the second-highest number of recovered patients. SARS-CoV-2 detection by real-time RT-PCR is the gold standard in certified infrastructured laboratories. However, for large-scale testing, diagnostics should be fast, cost-effective, widely available, and deployed for the community, such as serological tests based on lateral flow immunoassay (LFIA) for IgM/IgG detection. We evaluated three different commercial point-of-care (POC) LFIAs for anti-SARS-CoV-2 IgM and IgG detection in capillary whole blood of 100 healthcare workers (HCW) previously tested by RT-PCR: 1) COVID-19 IgG/IgM BIO (Bioclin, Brazil), 2) Diagnostic kit for IgM/IgG Antibody to Coronavirus (SARS-CoV-2) (Livzon, China); and 3) SARS-CoV-2 Antibody Test (Wondfo, China). A total of 84 positives and 16 negatives HCW were tested. The data was also analyzed by the number of days after symptoms (DAS) in three groups: <30 (n=26), 30-59 (n=42), and >59 (n=16). Overall detection was 85.71%, 47.62%, and 44.05% for Bioclin, Livzon, and Wondfo, respectively, with a specificity of 100%, and 98.75% for Livzon on storage serum samples. Bioclin was more sensitive (p<0.01), regardless of the DAS. Thus, the Bioclin can be used as a POC test to monitor SARS-CoV-2 seroconversion in HCW. +
++Following its emergence in late 2019, SARS-CoV-2 has caused a global pandemic resulting in unprecedented efforts to reduce transmission and develop therapies and vaccines. Rapidly generated viral genome sequences have allowed the spread of the virus to be tracked via phylogenetic analysis. While the virus spread globally in early 2020 before borders closed, intercontinental travel has since been greatly reduced, allowing continent-specific variants to emerge. However, within Europe travel resumed in the summer of 2020, and the impact of this travel on the epidemic is not well understood. Here we report on a novel SARS-CoV-2 variant, 20A.EU1, that emerged in Spain in early summer, and subsequently spread to multiple locations in Europe, accounting for the majority of sequences by autumn. We find no evidence of increased transmissibility of this variant, but instead demonstrate how rising incidence in Spain, resumption of travel across Europe, and lack of effective screening and containment may explain the variant9s success. Despite travel restrictions and quarantine requirements, we estimate 20A.EU1 was introduced hundreds of times to countries across Europe by summertime travellers, likely undermining local efforts to keep SARS-CoV-2 cases low. Our results demonstrate how genomic surveillance is critical to understanding how travel can impact SARS-CoV-2 transmission, and thus for informing future containment strategies as travel resumes. +
++Background: The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods: We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age range and incidence region. COVID-19 disease prevalence was compared between treated and untreated-matched control sample. Results: A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence of declared COVID-19 status in the treated group was 5.3% and the mean prevalence among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value=0.027). Conclusion: We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection and must take the same protection measures as the general population. +
++Objective: Patients with autoimmune diseases were advised to shield to avoid COVID-19, but information on their prognosis is lacking. We characterised 30-day outcomes and mortality after hospitalisation with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. Design: Multinational network cohort study Setting: Electronic health records data from Columbia University Irving Medical Center (CUIMC) (NYC, United States [US]), Optum [US], Department of Veterans Affairs (VA) (US), Information System for Research in Primary Care-Hospitalisation Linked Data (SIDIAP-H) (Spain), and claims data from IQVIA Open Claims (US) and Health Insurance and Review Assessment (HIRA) (South Korea). Participants: All patients with prevalent autoimmune diseases, diagnosed and/or hospitalised between January and June 2020 with COVID-19, and similar patients hospitalised with influenza in 2017-2018 were included. Main outcome measures: 30-day complications during hospitalisation and death Results: We studied 133,589 patients diagnosed and 48,418 hospitalised with COVID-19 with prevalent autoimmune diseases. The majority of participants were female (60.5% to 65.9%) and aged ≥50 years. The most prevalent autoimmune conditions were psoriasis (3.5 to 32.5%), rheumatoid arthritis (3.9 to 18.9%), and vasculitis (3.3 to 17.6%). Amongst hospitalised patients, Type 1 diabetes was the most common autoimmune condition (4.8% to 7.5%) in US databases, rheumatoid arthritis in HIRA (18.9%), and psoriasis in SIDIAP-H (26.4%). Compared to 70,660 hospitalised with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2.2% to 4.3% versus 6.3% to 24.6%). Conclusions: Patients with autoimmune diseases had high rates of respiratory complications and 30-day mortality following a hospitalization with COVID-19. Compared to influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality. Future studies should investigate predictors of poor outcomes in COVID-19 patients with autoimmune diseases. +
+Ivermectin for Severe COVID-19 Management - Condition: COVID-19
Intervention: Drug: Ivermectin
Sponsors: Afyonkarahisar Health Sciences University; NeuTec Pharma
Completed
A Phase Ⅱ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells) - Condition: COVID-19
Interventions: Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen; Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen; Biological: Low-dose placebo (18-59 years) & Two dose regimen; Biological: Low-dose placebo (18-59 years) & Three dose regimen; Biological: High-dose placebo (18-59 years) & Two dose regimen; Biological: High-dose placebo (18-59 years) & Three dose regimen; Biological: Low-dose placebo (60-85 years) & Two dose regimen; Biological: Low-dose placebo (60-85 years) & Three dose regimen; Biological: High-dose placebo (60-85 years) & Two dose regimen; Biological: High-dose placebo (60-85 years) & Three dose regimen
Sponsors: Jiangsu Province Centers for Disease Control and Prevention; West China Hospital
Recruiting
Adaptive COVID-19 Treatment Trial 4 (ACTT-4) - Condition: COVID-19
Interventions: Drug: Baricitinib; Drug: Dexamethasone; Other: Placebo; Drug: Remdesivir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India - Condition: COVID-19
Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol); Dietary Supplement: Zinc (zinc gluconate); Dietary Supplement: Zinc (zinc gluconate) & Vitamin D (cholecalciferol); Other: Placebo
Sponsors: Harvard School of Public Health; Foundation for Medical Research; University Health Network, Toronto
Not yet recruiting
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection - Condition: COVID-19
Intervention: Drug: GNS561
Sponsor: Genoscience Pharma
Recruiting
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness - Condition: COVID-19
Interventions: Drug: LY3819253; Drug: LY3832479; Drug: Placebo
Sponsors: Eli Lilly and Company; AbCellera Biologics Inc.; Shanghai Junshi Bioscience Co., Ltd.
Recruiting
A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19 - Condition: COVID-19
Interventions: Drug: Placebo Administration; Biological: Vaccine Therapy
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
Early Versus Delayed Intubation of Patients With COVID-19 - Conditions: COVID-19; Acute Hypoxemic Respiratory Failure
Intervention: Other: Endotracheal intubation
Sponsor: Evangelismos Hospital
Not yet recruiting
Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) - Condition: COVID-19
Interventions: Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14; Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28; Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14; Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28; Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#; Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#; Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#; Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#
Sponsors: Jiangsu Province Centers for Disease Control and Prevention; Academy of Military Medical Sciences，Academy of Military Sciences，PLA; ZHONGYIANKE Biotech Co, Ltd.; LIAONINGMAOKANGYUAN Biotech Co, Ltd
Recruiting
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica - Condition: COVID-19, Convalescent Plasma Treatment
Intervention: Biological: Convalescent Plasma Infusion
Sponsor: The University of The West Indies
Not yet recruiting
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS - Conditions: COVID-19; ARDS
Intervention: Drug: Losartan 50 mg and Spironolactone 25 mg pillules oral use
Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting
Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 Moves Through the Body of Adult Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) - Condition: CoronaVirus Disease-2019 (COVID-19)
Interventions: Drug: ABBV-47D11; Drug: Placebo for ABBV-47D11
Sponsor: AbbVie
Not yet recruiting
BCG Vaccination to Prevent COVID-19 - Condition: COVID-19
Interventions: Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine; Drug: Preservative-free saline
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Harvard Medical School; Uniformed Services University of the Health Sciences; United States Department of Defense; Defense Health Agency
Not yet recruiting
Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness - Condition: COVID-19 Convalescent Plasma Treatment
Intervention: Biological: COVID-19 convalescent plasma treatment
Sponsors: Wroclaw Medical University; Medical Research Agency
Not yet recruiting
Fase I Clinical Trial on NK Cells for COVID-19 - Conditions: Covid19; Sars-cov 2
Intervention: Biological: Natural Killer Cells infusion
Sponsor: Hospital de Clinicas de Porto Alegre
Not yet recruiting
MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection - COVID-19 affects vulnerable populations including elderly individuals and patients with cancer. Natural Killer (NK) cells and innate-immune TRAIL suppress transformed and virally-infected cells. ACE2, and TMPRSS2 protease promote SARS-CoV-2 infectivity, while inflammatory cytokines IL-6, or G-CSF worsen COVID-19 severity. We show MEK inhibitors (MEKi) VS-6766, trametinib and selumetinib reduce ACE2 expression in human cells. In some human cells, remdesivir increases ACE2-promoter…
N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects - In 2014, we reported two siblings with a rare congenital disorder of glycosylation due to mutations in mannosyl-oligosaccharide glucosidase (MOGS). The glycan alteration derived from this disease resulted in an in vitro infection resistance to particular enveloped, N-glycosylation-dependent viruses as influenza and HIV. As part of the global effort to find safe and effective antiviral therapies for Covid-19, we assessed the in vitro activity of the FDA-approved α-glucosidase inhibitor miglustat…
JAK-STAT pathway inhibition and their implications in COVID-19 therapy - As the incidence of COVID-19 increases with time, more and more efforts are made to pave a way out for the therapeutic strategies to deal with the disease progression. Inflammation being a significant influencer has implicated us to re-look into its signaling cascades drawing attention towards the JAK/STAT pathway. Considered as a major signaling mediator of cytokines and chemokines, the JAK/STAT pathway has significantly contributed to the worsening of COVID-19. JAK phosphorylation mediated by…
A Case-Control Study of the 2019 Influenza Vaccine and Incidence of COVID-19 Among Healthcare Workers - CONCLUSIONS: Significant findings suggest that the 2019 influenza vaccine may have a protective association against COVID-19 among HCW.
HDL-scavenger receptor B type 1 facilitates SARS-CoV-2 entry - Responsible for the ongoing coronavirus disease 19 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through binding of the viral spike protein (SARS-2-S) to the cell-surface receptor angiotensin-converting enzyme 2 (ACE2). Here we show that the high-density lipoprotein (HDL) scavenger receptor B type 1 (SR-B1) facilitates ACE2-dependent entry of SARS-CoV-2. We find that the S1 subunit of SARS-2-S binds to cholesterol and possibly to HDL…
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2’s main protease - CONCLUSION: Targeting of SARS-CoV-2 M^(pro) by some of the HIV PIs might be of limited clinical potential, given the high concentration of the drugs required to achieve significant inhibition. Therefore, given their weak inhibition of the viral protease, any potential beneficial effect of the PIs in COVID-19 context might perhaps be attributed to acting on other molecular target(s), rather than SARS-CoV-2 M^(pro).
Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection? - A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused a large disease outbreak in Wuhan, China in December 2019, is currently spreading across world’s many of the countries. Along with binding of the virus spike with the host cell receptor, fusion of the viral envelope with host cell membranes is a critical step in establishing successful infection of SARS-CoV-2. In this entry process, a diversity of host cell proteases and andro-gen receptor play a…
A novel COVID-19 epidemiological model with explicit susceptible and asymptomatic isolation compartments reveals unexpected consequences of timing social distancing - Motivated by the current COVID-19 epidemic, this work introduces an epidemiological model in which separate compartments are used for susceptible and asymptomatic “socially distant” populations. Distancing directives are represented by rates of flow into these compartments, as well as by a reduction in contacts that lessens disease transmission. The dynamical behavior of this system is analyzed, under various different rate control strategies, and the sensitivity of the basic reproduction number…
Translation of Mycobacterium Survival Strategy to Develop a Lipo-peptide based Fusion Inhibitor - The entry of enveloped viruses requires the fusion of viral and host cell membranes. An effective fusion inhibitor aiming at impeding such membrane fusion may emerge as a broad-spectrum antiviral agent against a wide range of viral infections. Mycobacterium survives inside the phagosome by inhibiting phagosome-lysosome fusion with the help of a coat protein coronin 1. Structural analysis of coronin 1 and other WD40-repeat protein suggest that the trp-asp (WD) sequence is placed at distorted…
Repurposing Anti-Cancer Drugs for COVID-19 Treatment - The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards…
Gammacoronavirus Avian Infectious Bronchitis Virus and Alphacoronavirus Porcine Epidemic Diarrhea Virus Exploit a Cell-Survival Strategy via Upregulation of cFOS to Promote Viral Replication - Coronaviruses have evolved a variety of strategies to optimize cellular microenvironment for efficient replication. In this study, we report the induction of AP-1 transcription factors by coronavirus infection based on genome-wide analyses of differentially expressed genes in cells infected with avian coronavirus infectious bronchitis virus (IBV). Most members of the AP-1 transcription factors were subsequently found to be upregulated during the course of IBV and porcine epidemic diarrhea virus…
Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19 - No definitive treatment for COVID-19 exists although promising results have been reported with remdesivir and glucocorticoids. Short of a truly effective preventive or curative vaccine against SARS-CoV-2, it is becoming increasingly clear that multiple pathophysiologic processes seen with COVID-19 as well as SARS-CoV-2 itself should be targeted. Because alpha-1-antitrypsin (AAT) embraces a panoply of biologic activities that may antagonize several pathophysiologic mechanisms induced by…
Development of a nano-luciferase based assay to measure the binding of SARS-CoV-2 spike receptor binding domain to ACE-2 - To identify drugs that could potentially be used to treat infection with SARS-CoV-2, a high throughput 384-well assay was developed to measure the binding of the receptor binding domain (RBD) of the viral S1 protein to its main receptor, angiotensin converting enzyme 2 (ACE2). The RBD was fused to both a HiBIT tag and an IL6 secretion signal to enable facile collection from the cell culture media. The addition of culture media containing this protein, termed HiBIT-RBD, to cells expressing ACE2…
Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020 - Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3-June 19, 2020, and again…
Bacillus Calmette-Guerin vaccination Policy and Consumption of Ammonium Chloride-Enriched Confectioneries May Be Factors Reducing COVID-19 Death Rates in Europe - CONCLUSIONS: The results seem to confirm an association between BCG-positive vaccination policy and salmiak consumption, and lower death rates from COVID-19. Implementing BCG vaccination policy and fortification of foods with salmiak (NH4Cl) may have a significant impact on the control of SARS-CoV epidemic.
AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19 -
SARS-CoV-2 예방을 위한 mRNA기반 항원보강제 혼합물 합성 방법 - 본 발명은 SARS-CoV-2(코로나 바이러스) 예방을 위한 mRNA 항원보강제에 관한 것으로 코로나 바이러스에 대한 백신으로서 상기의 항원에 대한 예방을 목적으로 하고 있다. 아이디어에는 보강제에 해당하는 완전프로인트항원보강제(CFA)와 불완전프로인트항원보강제(IFA), 번역과 안정성의 최적화가 된 mRNA, mRNA 운반체, 양이온성 지질 나노입자(lipid nanoparticles)로 구성되며 기존의 백신에 비해 효율성과 안정성의 측면에서 더 향상된 효과를 가지고 있다.
Vorrichtung zum Reinigen und/oder Desinfizieren von Objekten -
++
Vorrichtung (1) zum Desinfizieren von Objekten mit einer Basiseinheit (2), mit einem Aufnahmebehälter (4) für Wasser, welcher an der Basiseinheit (2) montierbar und von der Basiseinheit demontierbar ist, mit einer Objekthalterung (6) zum Halten und/oder Stützen der Objekte (10), wobei diese Objekthalterung (6) in dem Aufnahmebehälter montierbar ist und mit einer elektrisch betriebenen Reinigungseinrichtung (8), welche in dem Wasser befindliche Objekte zumindest mittelbar reinigt oder desinfiziert, wobei diese Reinigungseinrichtung in der Basiseinheit befindliche Erzeugungsmittel zum Erzeugen einer elektrischen Spannung aufweist sowie einen Plasmagenerator und/oder eine Ultraschallerzeugungseinheit.
wherein the ’ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
++Atemschutz-Baukastensystem, das aufweist:
+Vorrichtung zur Übergabe von mit Krankheitserregern kontaminierten Gegenständen oder Erzeugnissen nach einer Dekontamination, umfassend eine Einrichtung zur Dekontamination der mit Krankheitserregern kontaminierten Gegenstände oder Erzeugnisse mit mindestens einer UV-Strahlungsquelle (24), eine Durchzugseinrichtung mit Ein- und/oder Ausgabebereichen für die kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse, dadurch gekennzeichnet, dass die Durchzugseinrichtung im Eingang bzw. im Ausgang zum Ein- und/oder Ausgabebereich angeordnete sich paarweise gegenüberliegende Walzen (17) und Räder (4) umfasst, die zum Einzug bzw. zur Ausgabe der kontaminierten bzw. dekontaminierten Gegenstände oder Erzeugnisse vorgesehen sind, wobei die Walzen (17) und die Räder (4) durch im Ein- und/oder Ausgabebereich angeordnete Sensoren (23) und einer elektronische Kontrolleinheit (27) in Bewegung bringbar sind, wobei die Gegenstände oder Erzeugnisse in den Bereich der Einrichtung zur Dekontamination förderbar sind, der zwischen den paarweise angeordneten Walzen (17) und Rädern (4) vorgesehen ist, welcher sich gegenüberliegende Platten (25) aus Quarzglas oder einem UV-transparenten Polymermaterial, wie Graphen oder Kunstglas umfasst, über bzw. unter welchen die UV-Strahlungsquelle (24) angeordnet ist, welche als UVC-LED-Leiste und/oder Modul mit mindestens einer LED-Lampe ausgebildet ist.
제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물 - 본 발명은 화학식 1로 표시되는 화합물, 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환 예방 또는 치료용 약학적 조성물을 제공한다. [화학식 1] .
+ JPEG
+ 112020094463686-pat00017.jpg
+ 48
+ 135新型冠状病毒中和性抗体滴度检测ELISA试剂盒 - 本发明提供一种新型冠状病毒中和性抗体滴度检测ELISA试剂盒，其中包括：包被有生物素‑链霉亲和素标记的人ACE2蛋白的酶标板、辣根过氧化酶标记的新型冠状病毒RBD蛋白、新型冠状病毒中和性抗体阳性对照、包被液、洗涤液、稀释液、封闭液、显色液和终止液等。该试剂盒具有成本低，操作简单，高灵敏度、高特异性、高准确度的特点，可用于新型冠状病毒中和抗体的批量、快速检测。
Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion -
++
Diagnostisch nützlicher Träger umfassend ein Polypeptid umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SEQ ID NO1 aus einer Probe von einem Patienten binden kann, der an einer SARS-CoV-2-Infektion leidet, wobei das Polypeptid bevorzugt auf der Festphase des Trägers immobilisiert ist.
+Verwendung eines Polypeptides umfassend SEQ ID NO1 oder eine Variante davon, die an einen Antikörper gegen SED ID NO1 aus einer Probe von einem Patienten binden kann, zur Herstellung eines diagnostischen Kits.
Please - Comments
Tony Hsieh has died - Comments
Apple Silicon M1: A Developer’s Perspective - Comments
How the self-esteem craze took over America - Comments
Radical new bike chain claims to be faster, more durable than anything available - Comments
The great Internet TCP congestion control census - Comments
FlashFloppy: Open-source Firmware for floppy emulators - Comments
Summary of the Amazon Kinesis Event in the Northern Virginia (US-East-1) Region - Comments
Datasette-ripgrep: a regular expression search engine for your source code - Comments
Lisp Koans - Comments
Trump’s Final Cruelty: Executing Prisoners - Despite losing the election, the Administration plans to put Brandon Bernard and four other federal prisoners to death.
Trump and a Lesson in How Coups Fail - In countries without free elections, fraud and coercion regularly make a difference. But that’s not the country we have, and it’s not the election we had.
Is College Football Making the Pandemic Worse? - The game has a remarkable power to bring people together. Right now, that’s a problem.
Trump’s Battle to Undermine the Vote in Pennsylvania - Republicans in the state have alleged fraud and attempted to audit ballots. “The long-term goal,” a Democratic legislator told me, was to “falsely delegitimize Joe Biden’s victory.”
Our Brains Explain the Season’s Sadness - A pandemic, compounded by simultaneous political, civil, and natural crises, is overwhelming human evolution’s greatest innovation.
Forest Flame wins Bangalore 1000 Guineas - S. Attaollahi-trained Forest Flame (Trevor up), won the Bangalore 1000 Guineas, the chief event of the races held here on Saturday (Nov. 28). The win
Premier League | Mahrez hat-trick as Manchester City thrash Burnley 5-0 yet again - This is the fourth straight time with the same scoreline between the two sides
Carlsen ahead - Nepomniachtchi blunders; not Nakamura’s day
Indian Super League 2020 | BFC-HFC fail to break deadlock - Second successive draw for Cuadrat’s side
Jeet, Dhruv occupy front row - Raghul quickest in Super Stock category
488 new cases in capital, 365 recover - Active cases in district at 4,548
Special teams formed to distribute postal ballots - 300 officials to be deployed in district, police officer to accompany each team
2021 Tamil Nadu Assembly elections | Rajinikanth likely to make announcement on November 30 - Actor calls meeting of Rajini Makkal Mandram office-bearers at Raghavendra Kalyana Mandapam.
Neyyar Dam police station squabble: ASI suspended - Inquiry finds ASI’s action amounts ‘to abuse of authority’
At 629, Kottayam posts its highest daily tally - Kollam reports 458 new cases, Alappuzha 309
France: Tear gas fired as protesters rally against police security bill - Protesters throw fireworks and set up barricades while police use tear gas in tense clashes in Paris.
Deadly flooding hits Sardinia after heavy rains - Footage shows rivers of mud in the town of Bitti, where at least three people have died.
Channel crossings: More officers to patrol French beaches - The UK and France agree new measures to help stop migrants crossing the Channel.
Wilton Gregory: Pope appoints first African American cardinal - Wilton Gregory is one of 13 new cardinals installed by Pope Francis at a ceremony on Saturday.
Swiss vote on making firms liable for rights abuse - Many in government and business are wary, but campaigners say politicians are out of touch.
How many turkey feathers does it take to make an ancient blanket? 11,500 - You’d need the feathers from four to 10 turkeys, according to WSU anthropologists. - link
A mildly insane idea for disabling the coronavirus - What happens when you set biotechnologists loose without any practicality limits? - link
That time Roger Ebert said games will never be as worthy as movies - From the archives: 15 years ago around Thanksgiving, Ebert set video game Internet ablaze. - link
Linus Torvalds doubts Linux will get ported to Apple M1 hardware - “I’d absolutely love to have [an M1 laptop] if it just ran Linux,” Torvalds said. - link
Apple’s M1 MacBook Air has that Apple Silicon magic - Review: No piece of hardware is perfect, but man, this is a hell of a laptop. - link
6 yr old son made this up. What do exploding pandas eat? -
++BAMBOOM! +
+ submitted by /u/Fwooshersimmo
[link] [comments]
A balding white haired man walks into a jewelry store with a beautiful much younger gal at his side… -
++He told hte jeweler he was looking for a special ring for his girlfriend. The jeweler looked through his stock and brought out a $5,000 ring. +
++The man said, ‘No, I’d like to see something more special.’ +
++At that statement, the jeweler went to his special stock and brought another ring over.’Here’s a stunning ring at only $40,000the jeweler said. The lady’s eyes sparkled and her whole body trembled with excitement. The old man seeing this said, ‘We will take it.’ The jeweler asked how payment would be made and the man stated, ‘By check.I know you need to make sure my check is good, so I will write it now and you can call the bank Monday to verify the funds; I will pick the ring up Monday afternoon.’ +
++On Monday morning, the jeweler angrily phoned the old man and said ’Sir…There’s no money in that account. +
++‘’I know,’ said the old man…‘But let me tell you about my weekend.’ +
+ submitted by /u/X0ttaby4
[link] [comments]
It was George the Mailman’s last day on the job after 35 years of carrying the mail through all kinds of weather to the same neighborhood. When he arrived at the first house on his route, he was greeted by the whole family who congratulated him and sent him on his way with a tidy gift envelope. -
++At the second house, they presented him with a box of fine cigars. The folks at the third house handed him a selection of terrific fishing lures. +
++At the fourth house, he was met at the door by a strikingly beautiful blonde woman in a revealing negligee. She took him by the hand, gently led him through the door, which she closed behind him, and took him up the stairs to the bedroom where she blew his mind with the most passionate love he had ever experienced. +
++When he had enough, they went downstairs and she fixed him a giant breakfast: eggs, potatoes, ham, sausage, blueberry waffles, and fresh-squeezed orange juice. When he was truly satisfied, she poured him a cup of steaming coffee. As she was pouring, he noticed a dollar bill sticking out from under the cup’s bottom edge. ‟All this was just too wonderful for words,” he said, ‟But what’s the dollar for?” ‟Well,” she said, ‟Last night, I told my husband that today would be your last day, and that we should do something special for you. I asked him what to give you. He said, ’Screw him. Give him a dollar.’ The breakfast was my idea.” +
+ submitted by /u/QuitePeep
[link] [comments]
A guy walks into a bar with 10 bucks and asks what he can get -
++The bartender says, “You can get those damn deer the fuck outta my bar!” +
+ submitted by /u/penguinz-and-WHALE
[link] [comments]
a roman citizen walks into a bar raises two fingers and says to the waiter, -
++“five beers, please” +
+ submitted by /u/processocivil42
[link] [comments]